WO1998052590A3 - Improved delivery of disease modifiers - Google Patents
Improved delivery of disease modifiers Download PDFInfo
- Publication number
- WO1998052590A3 WO1998052590A3 PCT/CA1998/000448 CA9800448W WO9852590A3 WO 1998052590 A3 WO1998052590 A3 WO 1998052590A3 CA 9800448 W CA9800448 W CA 9800448W WO 9852590 A3 WO9852590 A3 WO 9852590A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- improved delivery
- disease modifiers
- disease
- hyaluronan
- modifiers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54972998A JP2001526666A (en) | 1997-05-22 | 1998-05-11 | Improved release of disease modulators |
EP98920426A EP0998297A2 (en) | 1997-05-22 | 1998-05-11 | Improved delivery of disease modifiers |
NZ501270A NZ501270A (en) | 1997-05-22 | 1998-05-11 | Pharmaceutical composition comprising hyaluronan (Mr less than 750,00) and a disease modifier (cytokine, a peptide mimicking a cytokine or a protein mimicking a cytokine) to enhance delivery of disease modifiers |
AU73286/98A AU740631B2 (en) | 1997-05-22 | 1998-05-11 | Improved delivery of disease modifiers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,205,771 | 1997-05-22 | ||
CA002205771A CA2205771C (en) | 1997-05-22 | 1997-05-22 | Improved delivery of disease modifiers |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998052590A2 WO1998052590A2 (en) | 1998-11-26 |
WO1998052590A3 true WO1998052590A3 (en) | 1999-04-22 |
Family
ID=4160694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1998/000448 WO1998052590A2 (en) | 1997-05-22 | 1998-05-11 | Improved delivery of disease modifiers |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0998297A2 (en) |
JP (1) | JP2001526666A (en) |
AU (1) | AU740631B2 (en) |
CA (1) | CA2205771C (en) |
NZ (1) | NZ501270A (en) |
WO (1) | WO1998052590A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
US20030082586A1 (en) | 1999-06-29 | 2003-05-01 | Millennium Pharmaceuticals, Inc. | Antibodies having diagnostic, preventive, therapeutic, and other uses |
WO2001080899A2 (en) * | 2000-04-20 | 2001-11-01 | Cangene Corporation | Rhamm peptide conjugates |
WO2004104166A2 (en) * | 2003-05-07 | 2004-12-02 | La Jolla Institute For Molecular Medicine | Administration of hyaluronic acid to enhance the function of transplanted stem cells |
DE102011122236A1 (en) * | 2011-12-09 | 2013-06-13 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Composition useful e.g. in topical treatment of inflammatory diseases of skin and/or mucous membrane, comprises fusafungine and its derivate, and acidic glycosaminoglycan or its derivatives |
FR3002452B1 (en) * | 2013-02-28 | 2016-02-12 | Dermaconcept Jmc | TOPIC ANTIMICROBIAL DERMATOLOGICAL COMPOSITION |
CN108137681B (en) | 2015-09-23 | 2024-06-18 | 豪夫迈·罗氏有限公司 | Optimized variants of anti-VEGF antibodies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004058A2 (en) * | 1989-09-21 | 1991-04-04 | Norpharmco Inc. | Treatment of conditions and disease |
WO1993021312A1 (en) * | 1992-04-09 | 1993-10-28 | University Of Manitoba | Hyaluronan receptor (rhamm = receptor for hyluronan mediated mobility) and hyaluronan binding peptides |
WO1996006622A1 (en) * | 1991-07-03 | 1996-03-07 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
-
1997
- 1997-05-22 CA CA002205771A patent/CA2205771C/en not_active Expired - Fee Related
-
1998
- 1998-05-11 AU AU73286/98A patent/AU740631B2/en not_active Ceased
- 1998-05-11 WO PCT/CA1998/000448 patent/WO1998052590A2/en not_active Application Discontinuation
- 1998-05-11 EP EP98920426A patent/EP0998297A2/en not_active Withdrawn
- 1998-05-11 NZ NZ501270A patent/NZ501270A/en unknown
- 1998-05-11 JP JP54972998A patent/JP2001526666A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004058A2 (en) * | 1989-09-21 | 1991-04-04 | Norpharmco Inc. | Treatment of conditions and disease |
WO1996006622A1 (en) * | 1991-07-03 | 1996-03-07 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
WO1993021312A1 (en) * | 1992-04-09 | 1993-10-28 | University Of Manitoba | Hyaluronan receptor (rhamm = receptor for hyluronan mediated mobility) and hyaluronan binding peptides |
Also Published As
Publication number | Publication date |
---|---|
AU7328698A (en) | 1998-12-11 |
CA2205771A1 (en) | 1998-11-22 |
NZ501270A (en) | 2001-08-31 |
AU740631B2 (en) | 2001-11-08 |
JP2001526666A (en) | 2001-12-18 |
CA2205771C (en) | 2002-05-14 |
WO1998052590A2 (en) | 1998-11-26 |
EP0998297A2 (en) | 2000-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1304346A3 (en) | Conjugate of polyethylene glycol and chitosan | |
EP0809996A3 (en) | Interferon conjugates | |
AU2075897A (en) | Delivery system using mab 3e10 and mutants and/or functional fragments thereof | |
AU7678196A (en) | Methods and compositions for the delivery of monomeric proteins | |
WO1993025583A3 (en) | Proteinoid carriers and methods for preparation and use thereof | |
EP0875252A3 (en) | Activated protein C formulations | |
SI0817621T1 (en) | Pharmaceutical composition for transdermic delivery | |
EP0841932A4 (en) | Drug delivery enhancement via modified saponins | |
AU1180997A (en) | Novel taxoids, their preparation and pharmaceutical compositions containing them | |
AU4770596A (en) | Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products | |
HK1029124A1 (en) | Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them. | |
WO1999040112A8 (en) | Neuroprotective peptides and uses thereof | |
AU4468197A (en) | Hyaluronic drug delivery system | |
CA2263181A1 (en) | Anti-chlamydial methods and materials | |
WO1998019697A3 (en) | Novel pharmaceutical compositions | |
HRP950612B1 (en) | PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | |
EP0950708A3 (en) | Enhanced affinity hyaluronan binding peptides | |
AU6175398A (en) | New delivery system for administering dentin-hypersensitivity-ameliorating compositions | |
WO1998052590A3 (en) | Improved delivery of disease modifiers | |
WO2000076528A3 (en) | Pharmaceutical preparation containing proteins | |
AU2975899A (en) | Colonic delivery of protein or peptide compositions | |
HK1029928A1 (en) | Pharmaceutical compositions of peptides having lowsolubility in physiological medium. | |
AU2420997A (en) | Oligopeptides for drug delivery | |
AU7000896A (en) | Novel peptide compounds and medicinal compositions thereof | |
AU3354797A (en) | Novel anticoagulant glycosides and pharmaceutical compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 549729 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 73286/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998920426 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 501270 Country of ref document: NZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998920426 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09424292 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 73286/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998920426 Country of ref document: EP |